Atea to Showcase Bemnifosbuvir-Ruzasvir and AT-587 Data at EASL Congress
Atea Pharmaceuticals will present three abstracts at the EASL Congress May 27–30 on its bemnifosbuvir-ruzasvir fixed-dose HCV regimen and top-poster preclinical data for AT-587 HEV inhibitor. It expects topline results from Phase 3 C-BEYOND and C-FORWARD and will advance AT-587 into clinical studies mid-year.
1. EASL Congress Presentations
Atea Pharmaceuticals will present three abstracts at the EASL Congress in Barcelona May 27–30. The sessions include two posters on its fixed-dose bemnifosbuvir-ruzasvir regimen for hepatitis C and a top-poster presentation of preclinical data for AT-587, underscoring progress across its viral hepatitis pipeline.
2. Bemnifosbuvir-Ruzasvir Fixed-Dose HCV Regimen
Poster FRI-635 demonstrates that omeprazole does not affect plasma pharmacokinetics of the fixed-dose combination, while FRI-636 shows low potential for P-gp, BCRP and OATP1B1/3 transport inhibition. These findings reinforce the differentiated target profile as Atea approaches topline results from its Phase 3 C-BEYOND and C-FORWARD trials.
3. AT-587 Preclinical Data and Development
Poster TOP-631 highlights AT-587 as a first-in-class, potent nucleotide analog inhibitor of hepatitis E virus selected as Atea’s lead HEV candidate. Designated a top-poster, the data support advancing AT-587 into first-in-human studies mid-year to address the unmet need in immunocompromised HEV patients.